Stents with anchoring sections

Information

  • Patent Grant
  • 10500042
  • Patent Number
    10,500,042
  • Date Filed
    Wednesday, May 20, 2015
    9 years ago
  • Date Issued
    Tuesday, December 10, 2019
    5 years ago
Abstract
A stent (300, 400, 400′) for a prosthetic heart valve includes a body having an inflow end (310, 410) and an outflow end (312, 412), and an anchoring section (340, 440) adjacent the inflow end. The anchoring section may include structure (342, 344, 420) that extends radially outwardly from the body when the stent is in an expanded condition. The stent may include a transition section (370, 470) between the body and the anchoring section, the transition section in the expanded condition of the stent having a diameter that is smaller than the diameters of the body and the anchoring section. When implanted into a native valve annulus, such as the mitral valve annulus, the anchoring section may help the stent resist migrating away from the native valve annulus.
Description
BACKGROUND

The present disclosure relates to heart valve replacement and, in particular, to collapsible prosthetic heart valves. More particularly, the present disclosure relates to prosthetic heart valves that facilitate secure positioning within a native valve annulus.


Prosthetic heart valves that are collapsible to a relatively small circumferential size can be delivered into a patient less invasively than valves that are not collapsible. For example, a collapsible valve may be delivered into a patient via a tube-like delivery apparatus such as a catheter, a trocar, a laparoscopic instrument, or the like. This collapsibility can avoid the need for a more invasive procedure such as full open chest, open heart surgery.


Collapsible prosthetic heart valves typically take the form of a valve structure mounted on a stent. There are two types of stents on which the valve structures are ordinarily mounted: a self-expanding stent and a balloon-expandable stent. To place such valves into a delivery apparatus and ultimately into a patient, the valve is generally first collapsed or crimped to reduce its circumferential size.


When a collapsed prosthetic valve has reached the desired implant site in the patient (e.g., at or near the annulus of the patient's heart valve that is to be replaced by the prosthetic valve), the prosthetic valve can be deployed or released from the delivery apparatus and re-expanded to full operating size. For balloon expandable valves, this generally involves releasing the entire valve, assuring its proper location, and then expanding a balloon positioned within the valve stent. For self-expanding valves, on the other hand, the stent automatically expands as the sheath covering the valve is withdrawn.


BRIEF SUMMARY

According to one embodiment of the disclosure, a stent includes an inflow end, an outflow end, a body section extending from the outflow end toward the inflow end, and an anchoring section adjacent the inflow end having a first annular disc and a second annular disc. The stent may have a collapsed condition and an expanded condition. The first annular disc and the second annular disc may each extend radially outwardly from the body section when the stent is in the expanded condition.


According to another embodiment of the disclosure, a stent includes an inflow end, an outflow end, a body section extending from the outflow end toward the inflow end, an anchoring section adjacent the inflow end; and a transition section between the body section and the anchoring section. The transition section may have a diameter that is smaller than diameters of the body section and the anchoring section. The stent may have a collapsed condition, an expanded condition, and a longitudinal axis. The anchoring section may extend radially outwardly from the longitudinal axis when the stent is in the expanded condition.





BRIEF DESCRIPTION OF THE DRAWINGS

Various embodiments of the present disclosure are described herein, with reference to the drawings, wherein:



FIG. 1 is a schematic cutaway representation of a human heart showing a transapical delivery approach;



FIG. 2 is a schematic representation of a native mitral valve and associated cardiac structures;



FIG. 3A is a bottom perspective view of a stent of a prosthetic heart valve according to an embodiment of the disclosure;



FIG. 3B is a schematic representation of the stent of FIG. 3A disposed in a native valve annulus;



FIG. 4A is a front view of a front portion of a stent of a prosthetic heart valve according to another embodiment of the disclosure;



FIG. 4B is a schematic representation of the stent of FIG. 4A disposed in a native valve annulus; and



FIG. 4C is a front view of a front portion of a stent of a prosthetic heart valve according to a further embodiment of the disclosure.





Various embodiments of the present disclosure will now be described with reference to the appended drawings. It is to be appreciated that these drawings depict only some embodiments of the disclosure and are therefore not to be considered limiting of its scope.


DETAILED DESCRIPTION

Blood flows through the mitral valve from the left atrium to the left ventricle. As used herein, the term “inflow end,” when used in connection with a prosthetic atrioventricular heart valve, refers to the end of the heart valve closest to the atrium when the heart valve is implanted in a patient, whereas the term “outflow end,” when used in connection with a prosthetic atrioventricular heart valve, refers to the end of the heart valve closest to the ventricle when the heart valve is implanted in a patient. Further, when used herein with reference to a delivery device, the terms “proximal” and “distal” are to be taken as relative to a user using the device in an intended manner. “Proximal” is to be understood as relatively close to the user and “distal” is to be understood as relatively farther away from the user. Also, as used herein, the terms “substantially,” “generally,” and “about” are intended to mean that slight deviations from absolute are included within the scope of the term so modified. Generally, materials described as being suitable for components in one embodiment may also be suitable for similar components described in other embodiments. Although embodiments disclosed herein are generally described in relation to replacement of a native mitral valve, it should be understood that the disclosed embodiments and variants thereof may be suitable to replace other valves, including other heart valves such as the aortic or tricuspid valve. When ranges of values are described herein, those ranges are intended to include sub-ranges. For example, a recited range of 1 to 10 includes 2, 5, 7, and other single values, as well as ranges of 2 to 6, 3 to 9, 4 to 5, and others.



FIG. 1 is a schematic cutaway representation of human heart 100. The human heart includes two atria and two ventricles: right atrium 112 and left atrium 122, and right ventricle 114 and left ventricle 124. Heart 100 further includes aorta 110, and aortic arch 120. Disposed between the left atrium and the left ventricle is mitral valve 130. Mitral valve 130, also known as the bicuspid valve or left atrioventricular valve, is a dual-flap that opens as a result of increased pressure in left atrium 122 as it fills with blood. As atrial pressure increases above that of left ventricle 124, mitral valve 130 opens and blood passes into left ventricle 124. Blood flows through heart 100 in the direction shown by arrows “B”.


A dashed arrow, labeled “TA”, indicates a transapical approach of implanting a prosthetic heart valve, in this case to replace the mitral valve. In transapical delivery, a small incision is made between the ribs and into the apex of left ventricle 124 to deliver the prosthetic heart valve to the target site. A second dashed arrow, labeled “TS”, indicates a transseptal approach of implanting a prosthetic heart valve in which the valve is passed through the septum between right atrium 112 and left atrium 122. Other approaches for implanting a prosthetic heart valve are also possible and may be used in connection with the disclosed embodiments.



FIG. 2 is a more detailed schematic representation of native mitral valve 130 and its associated structures. As previously noted, mitral valve 130 includes two flaps or leaflets, posterior leaflet 136 and anterior leaflet 138, disposed between left atrium 122 and left ventricle 124. Cord-like tendons, known as chordae tendineae 134, connect the two leaflets 136, 136 to the medial and lateral papillary muscles 132. During atrial systole, blood flows from higher pressure in left atrium 122 to lower pressure in left ventricle 124. When left ventricle 124 contracts in ventricular systole, the increased blood pressure in the chamber pushes leaflets 136, 138 to close, preventing the backflow of blood into left atrium 122. Since the blood pressure in left atrium 122 is much lower at this point in a heartbeat than that in left ventricle 124, leaflets 136, 138 attempt to evert to the low pressure regions. Chordae tendineae 134 prevent the eversion by becoming tense, thus pulling on leaflets 136, 138 and holding them in the closed position.


When a self-expanding prosthetic heart valve is implanted in a patient, for example at the annulus of a native heart valve, it generally is biased towards an expanded condition, providing radial force to anchor the valve in place. This may be true of prosthetic heart valves used to replace the aortic valve as well as those used to replace the mitral valve. When replacing the aortic valve, the radial force may anchor the prosthetic valve onto calcified native leaflets around the aortic root. When replacing the left atrioventricular valve (known as the mitral or bicuspid valve) or the right atrioventricular valve (known as the tricuspid valve), anchoring with radial force may be more challenging. This may be at least in part due to the fact that there is relatively little tissue in the left atrium adjacent the mitral valve to which a stent may anchor via radial force. This is also true of the area available in the right atrium adjacent the tricuspid valve. In contrast, there is a relatively large amount of solid tissue in the aorta adjacent the aortic valve available for anchoring a stent via radial force. For example, the aortic root, which is adjacent the aortic valve, may provide ample structure for anchoring a stent via radial force. In addition, if the radial force used to anchor a prosthetic heart valve is too high, damage may occur to heart tissue. If, instead, the radial force is too low, the heart valve may move from its implanted position. For example, a prosthetic mitral valve may migrate into left ventricle 124 or left atrium 122 if the radial force is too low, requiring emergency surgery to remove the displaced valve. The potential for such movement may be heightened in mitral valve applications, particularly if a low profile valve is used.


Another potential issue with prosthetic heart valves is inadequate sealing between the prosthetic valve and the native tissue. For example, if a prosthetic heart valve is implanted at the annulus of mitral valve 130 in a patient, improper or inadequate sealing may result in blood flowing from left ventricle 124 into left atrium 122, even if the prosthetic leaflets of the valve assembly are working properly. This may occur, for example, if blood flows in a retrograde fashion between the outer perimeter of the prosthetic heart valve and the native tissue at the site of implantation. This phenomenon is known as perivalvular (or paravalvular) leak (“PV leak”).



FIG. 3A illustrates a stent 300 of a prosthetic heart valve according to one embodiment of the disclosure. Stent 300 may be collapsible and expandable for use in a prosthetic heart valve intended to replace the function of a native heart valve of a patient, such as the mitral valve (see native mitral valve 130 of FIGS. 1-2). In FIG. 3A, stent 300 is illustrated in an expanded condition. The remaining components that would be attached to stent 300 to form a prosthetic heart valve, such as prosthetic valve leaflets and a cuff, are omitted from the figure for clarity.


Stent 300 may be formed from biocompatible materials that are capable of self-expansion, such as, for example, shape memory alloys including Nitinol. Generally, stent 300 extends from inflow end 310 to outflow end 312. A plurality of struts 320 may form cells 322 in stent 300, the cells being connected to one another in one or more annular rows around the stent. Cells 322 may all be of substantially the same size around the perimeter and along the length of stent 300. However, cells 322 nearer inflow end 310 may be larger or smaller than the cells nearer outflow end 312.


Stent 300 may have a body or leaflet section 330 extending from outflow end 312 toward inflow end 310. Leaflet section 330 may have a substantially cylindrical shape. When used in a prosthetic heart valve, prosthetic valve leaflets may be attached directly or indirectly to an inner surface of leaflet section 330. Leaflet section 330 may take other shapes, such as a substantially conical shape or a general “D”-shape, which may better correspond to the shape of the native valve annulus in which stent 300 is implanted.


As noted above, stent 300 may be provided with prosthetic valve leaflets. One, two, or more prosthetic valve leaflets may be included in a valve assembly attached to stout 300. The valve assembly may be substantially cylindrical, although other shapes may be suitable, and may include a cuff attached to leaflet section 330. The prosthetic leaflets may be attached to the cuff or directly to struts 320 of leaflet section 330. When used to replace a mitral valve, the prosthetic leaflets replace the function of native mitral valve leaflets 136 and 138 described above in connection with FIG. 2. That is, the prosthetic leaflets coapt with one another to function as a one-way valve. It should be appreciated that a prosthetic heart valve incorporating stout 300 may have more than two prosthetic leaflets when used to replace the mitral valve or other cardiac valves within a patient. Both the cuff and leaflets may be wholly or partly formed of any suitable biological material, such as bovine or porcine pericardium, or polymers, such as polytetrafluoroethylene (PTFE), urethanes and the like. The valve assembly may be secured to stent 300 by suturing to struts 320 or by using tissue glue, ultrasonic welding or other suitable methods.


An anchoring or clamp section 340 may be positioned adjacent the leaflet section 330 and inflow end 310. Clamp section 340 may include a first disc 342 and a second disc 344. Each disc 342, 344 may be generally annular and may take the form of a mesh or braid, including metal braids such as braided Nitinol. Alternatively, first disc 342 and/or second disc 344 may be formed of fabrics and/or polymers, such as PTFE, urethanes, and the like in still other embodiments, discs 342 and 344 may be formed of tissue, such as bovine or porcine cardiac tissue. Some or all of the above materials may be used in combination with a coating, such as a collagen coating, a fibrin coating, or a polymer coating (such as a silicone coating). In addition, while discs 342 and 344 may each be formed of the same material, disc 342 may be formed of any one of the materials described above while disc 344 may be formed of a different material described above. Disc 342 may be attached to inflow end 310 by, for example, sutures, metal pressed clamping, adhesives, ultrasonic welding, or other suitable methods. Disc 344 may be attached to disc 342 by any suitable method. Alternatively, discs 342 and 344 may be formed as a single unit from the same material. When discs 342 and 344 are both formed of the same material as stent 300, discs 342 and 344 may be formed as a single unit with the remainder of stent 300. Preferably, clamp section 340 is positioned in series with leaflet section 330. In other words, neither disc 342 nor disc 344 overlap struts 320 of stent 300 when the scent is in the collapsed condition. When in the expanded condition, there is no overlap or minimal overlap between the discs 342, 344 and the struts 320. As described in more detail below, this may help reduce the profile of stent 300 during delivery.


First disc 342 may be positioned closer to outflow end 312 than second disc 344, which may be positioned farther away from outflow end 312. The diameter of first disc 342 may be smaller than the diameter of second disc 344. In other words, second disc 344 may extend farther radially outwardly from a longitudinal axis L1 of stent 300. With this configuration, stent 300 may be implanted in a native mitral valve annulus VA with first disc 342 positioned within left ventricle 124 and second disc 344 positioned within left atrium 122, as illustrated in FIG. 35.


When positioned in the native mitral valve annulus VA, second disc 344 on the atrial side of native valve annulus VA helps anchor stent 300 in place, resisting migration into left ventricle 124. Similarly, first disc 342 on the ventricular side of native valve annulus VA helps resist migration of stent 300 into left atrium 122. The relatively large size of second disc 344 compared to first disc 342 may be useful in that there may be a greater anatomical area available for contact on the atrial side of native valve annulus VA. As a result, stent 300 may rely less on radial anchoring force and thus avoid some or all of the potential issues described above in connection with the use of radial force to anchor a prosthetic heart valve within a native valve annulus. If formed of a material that may be shape-set, first disc 342 may be shape-set, for example by heat setting, such that it flares or is biased away from outflow end 312. Similarly, second disc 344 may be shape-set such that it flares or is biased toward outflow end 312, In this configuration, first disc 342 and second disc 344 may act together to pinch native valve annulus VA. Such biasing, however, is not required. Thus, in other embodiments, one or both of first disc 342 and second disc 344 may extend at an angle of about 90 degrees from the longitudinal, axis L1L1 of stent 300 when stent 300 is in the relaxed or expanded condition. It should be understood that other angles or ranges of angles from longitudinal axis L1, for example between about 60 degrees and about 120 degrees, between about 70 degrees and about 110 degrees, or between about 80 degrees and about 100 degrees, may also be suitable.


The use of a mesh or braided wire to form first disc 342 and second disc 344 may provide a relatively large surface area with which the native anatomy may interact and into which tissue can grow, helping secure stent 300 further. This may result in both better anchoring and better sealing of the prosthetic heart valve incorporating stent 300. Additionally, sealing may be further improved by providing a fabric or other covering over first disc 342 and second disc 344, which may enhance tissue ingrowth and healing. In certain arrangements, such fabric or other covering may be applied only to first disc 342 or only to second disc 344.


As illustrated in FIG. 3B, first disc 342 and second disc 344 may be part of a single continuous mesh or braided structure, with the discs being at substantially opposite ends of the braided structure. However, each disc may be provided independently of the other. Whether separate structures or part of one continuous structure, a space between first disc 342 and second disc 344 defines an annulus gap 370 in which the native valve annulus VA is positioned when stent 300 is implanted. Having the first disc 342 and the second disc 344 on opposite ends of an annulus gap helps anchor stent 300 in the native valve annulus VA, and further may help restrict movement of native valve leaflets that may still be partially or fully intact.


When being used in a prosthetic heart valve for replacing the native mitral valve of a patient, stent 300 is crimped to a collapsed condition and positioned within a catheter or similar structure of a delivery device. The delivery device may, for example, be inserted through the apex of the heart (transapical delivery) or through the femoral artery and passed through the vasculature to the implant site (transfemoral delivery), although other delivery routes may be used. If a transapical method is used, retaining tabs 360 on outflow end 312 of stent 300 may be connected to the delivery device and may be configured to maintain a connection between stent 300 and the delivery device prior to full release of the stent. When stent 300 is crimped and in the collapsed condition, clamp section 340 extends away from leaflet section 330. Once the delivery device is near the site of implantation, the sheath or other member compressing stent 300 may be slowly retracted to reveal stent 300 and allow it to expand to the expanded condition. As the sheath is retracted, clamp section 340 may begin to expand prior to leaflet section 330, such that the proper positioning of first disc 342 and second disc 344 relative to the native valve annulus VA may be confirmed before continuing release of the stent. Once confirmed, retraction of the sheath may be continued to allow leaflet section 330, along with the valve assembly with prosthetic leaflets positioned therein, to expand into the implantation site. If the positioning is acceptable to the user, the sheath may be further retracted to release retaining tabs 360 to fully release stent 300 into the patient. If the positioning is not acceptable, the sheath may be advanced in the opposite direction to partially or completely resheathe stent 300. Once partially or fully resheathed, the user may attempt to properly position and release stent 300 again. Similarly, when using other delivery routes, such as a transseptal route, retaining tabs may be formed near inflow end 310 with the outflow end 312 being expanded first. Further, as shown in FIG. 3B, the valve 300 may be implanted such that leaflet section 330 is substantially or fully in a supraannular position. When used in the context of an atrioventricular valve, supraannular refers to a position closer to a position beyond the native valve annulus in the direction of the ventricle.


When implanting a collapsible prosthetic heart valve, the size of the prosthetic heart valve in the collapsed condition, including stent 300, may be an important factor. For example, a prosthetic heart valve that retains a large profile in the collapsed condition will need to be delivered using a delivery device with a correspondingly large catheter. On the other hand, a prosthetic heart valve with a small profile in the collapsed condition may be implanted using a delivery device with a correspondingly small catheter. If first disc 342 and/or second disc 344 were positioned along a portion of leaflet section 330, stent 300 would have a relatively large crimp profile and require a relatively large catheter. In the illustrated embodiment, clamp section 340 and leaflet section 330 are positioned in series such that, when crimped and loaded into a delivery device in the collapsed condition, most or all of first disc 342 and second disc 342 do not overlap with struts 320 of leaflet section 330. Avoiding this overlap facilitates a reduction in crimp profile, thus allowing relatively small catheters to be used to deliver and implant prosthetic heart valves incorporating stent 300.



FIG. 4A illustrates a stent 400 of a prosthetic heart valve according to another embodiment of the disclosure. Stent 400 may have features similar to stent 300. For example, stent 400 may be collapsible and expandable for use in a prosthetic heart valve intended to replace the function of a native heart valve of a patient. Stent 400 is illustrated in FIG. 4A in an expanded condition, omitting the back side of the stent for clarity, and omitting other components that could be attached to the stent to form a prosthetic heart valve, such as prosthetic valve leaflets and a cuff.


Stent 400 may be formed from biocompatible materials that are capable of self-expansion, including Nitinol or super-elastic polymeric materials. An inflow end 410 may be positioned on the opposite end of stent 400 than an outflow end 412. A plurality of struts 420 may form cells 422 connected to one another in one or more annular rows around the stent. As with stent 300, cells 422 of stent 400 may all be of substantially the same size around the perimeter and along the length of stent 400 or cells 422 nearer inflow end 410 may be larger or smaller than the cells nearer outflow end 412.


A prosthetic heart valve incorporating stent 400 may include prosthetic valve leaflets, such as those described above in connection with the embodiment of FIGS. 3A-B. The prosthetic valve leaflets may be attached to stent 400 at a body or leaflet section 430, which may extend from outflow end 412 toward inflow end 410. Leaflet section 430 may have a substantially cylindrical shape as illustrated in FIG. 4A, but may take other shapes.


While leaflet section 430 is positioned closer to outflow end 412 of stent 400, an anchor or flange section 440 is positioned adjacent inflow section 410. Flange section 440 may be integral with the remainder of stent 400 and may be defined at least in part by a plurality of cells 422 and/or struts 420 extending radially outwardly. The stent 400, including flange section 440, may be formed by laser cutting a single tube of material into the desired shape, although other methods of manufacture may be suitable. The cells 422 and/or struts 420 defining flange section 440 may be configured to extend at an angle of about 90 degrees from a longitudinal axis L2 of stent 400 when stent 400 is in the relaxed or expanded condition. It should be understood that other angles or ranges of angles, for example between about 60 degrees and about 120 degrees, between about 70 degrees and about 110 degrees, or between about 80 degrees and about 100 degrees, may also be suitable. It should further be noted that flange section 440 need not be integral with the remainder of stent 400, and may be attached to leaflet section 430 and formed of materials other than Nitinol. Flange section 440 transitions to leaflet section 430 via a reduced diameter transition section, referred to herein as annulus groove 470. When in the relaxed or expanded condition, the diameter D1 of stent 400 at the innermost portion of annulus groove 470 is smaller than the diameter of the flange section 440 and the diameter D2 of leaflet section 430. Preferably, when implanted, the diameter D1 of annulus groove 470 at the innermost portion is equal to or smaller than the diameter of native valve annulus VA, while diameter D2 is preferably larger than the inner diameter of the native valve annulus. This arrangement may facilitate better securement of stent 400 in the native anatomy, including the annulus and portions of native leaflets.


In use, a prosthetic heart valve incorporating stunt 400 may be positioned within a native valve annulus VA as illustrated in FIG. 4B, which omits from the illustration components of the prosthetic heart valve other than stent 400. When implanted, flange section 440 may be positioned in left atrium 122. The elastic properties of the struts forming flange section 440 and the above-described shape setting helps flange section 440 conform to the atrial surface of native valve annulus VA. During atrial systole when the prosthetic leaflets open, the forward force from left atrium 122 toward left ventricle 124 is relatively small and flange section 440 helps prevent the prosthetic heart valve incorporating stent 400 from slipping into left ventricle 124. Further, the innermost portion of annulus groove 470 is positioned adjacent native valve annulus VA, such that the sidewalls of annulus groove 470 perform a clamp-like function. During ventricular systole when the prosthetic leaflets close, the back pressure from left ventricle 124 toward left atrium 122 is relatively large. The annulus groove 470, in combination with the diameter D2 of leaflet section 430 being larger than the diameter of the native valve annulus VA, helps the valve resist slipping into left atrium 122.


As noted above, FIGS. 4A-B omit certain structures which may be used in addition to stent 400 to form a prosthetic heart valve. For example, one or more cuffs may be attached on flange section 430 and/or at annulus groove 470 to help prevent PV leak. The number of prosthetic leaflets within the leaflet section 430 may be one, two, three, or more. The cuffs and prosthetic leaflets may be formed of the same or similar materials as described above in connection with the embodiment of FIGS. 3A-B.


When being used in a prosthetic heart valve for replacing the native mitral valve of a patient, stent 400 is crimped to a collapsed condition and positioned within a catheter or similar structure of a delivery device prior to implantation. The method of delivering a prosthetic heart valve incorporating stent 400 may be substantially similar to that described in connection with stent 300 of FIGS. 3A-B. For example, if a transfemoral route of delivery is used, retaining tabs 460 on inflow end 410 of stent 400 may be connected to the delivery device to couple stent 400 to the delivery device until stent 400 is fully expanded. Retaining tabs (not illustrated) may be formed on outflow end 412 of stent 400, on the other hand, for retaining stent 400 in a delivery device during a transapical delivery. Further, the valve 400 may be implanted such that leaflet section 430 is substantially or fully in a supraannular position.


As noted above, although leaflet section 430 is illustrated with a substantially cylindrical shape in FIG. 4A, other shapes are possible. For example, leaflet body 430′ is illustrated in FIG. 4C as having a barrel shape. In other words, barrel-shaped leaflet section 430′ has a circumference that is larger (i.e., projects farther radially outward) in a center portion than it is on either side of the center portion. The barrel-shaped body may reduce the interference of stent 400′ with heart structures within a native ventricle. Further, as described above in connection with FIGS. 3A-B, leaflet section 430 may also be generally “D”-shaped to better conform to native annulus VA. For example, interference may be reduced in the sense that the relatively smooth barrel shape is less likely to “poke” or otherwise detrimentally engage with chordae tendinae or native leaflets.


Various modifications may be made to the embodiments disclosed herein without departing from the scope of the disclosure. For example, although stents and prosthetic heart valves are generally described for replacement of the mitral other bicuspid valves, variations may be made to these devices to replace tricuspid valves. Thus, the prosthetic valves may be provided with three leaflets, or more or fewer leaflets as desired. Similarly, although generally described as self-expanding prosthetic heart valves or stents, the principles described herein are also applicable to prosthetic valves that are not self-expanding, such as balloon-expandable prosthetic valves.


According to one embodiment of the disclosure, a stent has a collapsed condition and an expanded condition, the stent comprising a body having an outflow end and an inflow end; and an anchoring section adjacent the inflow end and including a first annular disc and a second annular disc, the first annular disc and the second annular disc each extending radially outwardly from the body when the stout is in the expanded condition; and/or


the first disc has a smaller diameter than the second disc when the stent is in the expanded condition; and/or


the second disc is positioned farther away from the outflow end than the first disc; and/or


the first disc and the second disc are each formed of a braided material; and/or


the braided material is Nitinol; and/or


the anchoring section includes a gap between the first disc and the second disc when the stent is in the expanded condition; and/or


the first disc is integral with the second disc; and/or


the first disc and the second disc are each integral with the body; and/or


there is substantially no overlap between the first disc and the body when the stent is in the collapsed condition; and/or


the first disc flares away from the outflow end and the second disc flares toward the outflow end when the stent is in the expanded condition; and/or


the first disc and the second disc each extend at an angle of about 90 degrees from a longitudinal axis of the body when the stent is in the expanded condition; and/or


a prosthetic heart valve having at least two prosthetic heart valve leaflets positioned within the body.


According to another embodiment of the disclosure, a stent has a collapsed condition and an expanded condition, the stent comprising a body having a longitudinal axis, an outflow end, an inflow end, and a diameter in the expanded condition of the stent; an anchoring section adjacent the inflow end, and the anchoring section having a diameter in the expanded condition of the stent; and a transition section between the body and the anchoring section, the transition section in the expanded condition of the stent having a diameter that is smaller than the diameter of the body and smaller than the diameter of the anchoring section, wherein the anchoring section extends radially outwardly from the longitudinal axis of the body when the stent is in the expanded condition; and/or


the anchoring section includes a plurality of struts forming cells; and/or


the anchoring section is integral with the body; and/or


the anchoring section extends radially outwardly from the longitudinal axis of the body at an angle of between about 80 degrees and about 100 degrees when the stent is in the expanded condition; and/or


the anchoring section extends radially outwardly from the longitudinal axis of the body at an angle of about 90 degrees when the stent is in the expanded condition; and/or


the body is substantially cylindrical; and/or


the body has a center portion between the inflow end and the outflow end, the center portion having a circumference that is larger than a circumference of the body on either side of the center portion when the stent is in the expanded condition; and/or


a prosthetic heart valve having at least two prosthetic heart valve leaflets positioned within the body.


It will be appreciated that the various dependent claims and the features set forth therein can be combined in different ways than presented in the initial claims. It will also be appreciated that the features described in connection with individual embodiments may be shared with others of the described embodiments.

Claims
  • 1. A stent having a collapsed condition and an expanded condition, the stent comprising: a body having an outflow end and an inflow end; andan anchoring section adjacent the inflow end and including a first annular disc and a second annular disc, the first annular disc and the second annular disc each extending radially outwardly from the body when the stent is in the expanded condition, the first and second annular discs each being formed of a braided material,the body including a plurality of struts forming cells, the body providing a surface for attachment of prosthetic valve leaflets so that the prosthetic valve leaflets radially overlap a portion of the body, the body and the anchoring section being positioned in series such that, in the collapsed condition of the stent, no portion of the first disc radially overlaps with any portion of the struts of the body and no portion of the second disc radially overlaps with any portion of the struts of the body.
  • 2. The stent of claim 1, wherein the first disc has a smaller diameter than the second disc when the stent is in the expanded condition.
  • 3. The stent of claim 2, wherein the second disc is positioned farther away from the outflow end than the first disc.
  • 4. The stent of claim 1, wherein the braided material is Nitinol.
  • 5. The stent of claim 1, wherein the anchoring section includes a gap between the first disc and the second disc when the stent is in the expanded condition.
  • 6. The stent of claim 1, wherein the first disc is integral with the second disc.
  • 7. The stent of claim 6, wherein the first disc and the second disc are each integral with the body.
  • 8. The stent of claim 1, wherein the first disc flares away from the outflow end and the second disc flares toward the outflow end when the stent is in the expanded condition.
  • 9. The stent of claim 1, wherein the first disc and the second disc each extend at an angle of about 90 degrees from a longitudinal axis of the body when the stent is in the expanded condition.
  • 10. A prosthetic heart valve comprising: a stent having a collapsed condition and an expanded condition, the stent having:a body having an outflow end and an inflow end; andan anchoring section adjacent the inflow end and including a first annular disc and a second annular disc, the first annular disc and the second annular disc each extending radially outwardly from the body when the stent is in the expanded condition, the first and second annular discs each being formed of a braided material,the body including a plurality of struts forming cells, the body providing a surface for attachment of prosthetic valve leaflets so that the prosthetic valve leaflets radially overlap a portion of the body, the body and the anchoring section being positioned in series such that, in the collapsed condition of the stent, no portion of the first disc radially overlaps with any portion of the struts of the body and no portion of the second disc radially overlaps with any portion of the struts of the body;and at least two prosthetic heart valve leaflets positioned within the body.
  • 11. The prosthetic heart valve of claim 10, wherein the at least two prosthetic heart valve leaflets are configured to be in a supraannular position with respect to a native valve annulus when implanted.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a national phase entry under 35 U.S.C. § 371 of International Application No. PCT/US2015/031691, filed May 20, 2015 which claims the benefit of the filing date of U.S. Provisional Application No. 62/001,793, filed May 22, 2014, entitled “STENTS WITH ANCHORING SECTIONS,” the disclosures of which are both hereby incorporated by reference herein.

PCT Information
Filing Document Filing Date Country Kind
PCT/US2015/031691 5/20/2015 WO 00
Publishing Document Publishing Date Country Kind
WO2015/179473 11/26/2015 WO A
US Referenced Citations (151)
Number Name Date Kind
3657744 Ersek Apr 1972 A
4275469 Gabbay Jun 1981 A
4491986 Gabbay Jan 1985 A
4759758 Gabbay Jul 1988 A
4878906 Lindemann et al. Nov 1989 A
4922905 Strecker May 1990 A
4994077 Dobben Feb 1991 A
5411552 Andersen et al. May 1995 A
5415664 Pinchuk May 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5843167 Dwyer et al. Dec 1998 A
5855601 Bessler et al. Jan 1999 A
5935163 Gabbay Aug 1999 A
5961549 Nguyen et al. Oct 1999 A
6077297 Robinson et al. Jun 2000 A
6083257 Taylor et al. Jul 2000 A
6090140 Gabbay Jul 2000 A
6214036 Letendre et al. Apr 2001 B1
6264691 Gabbay Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6368348 Gabbay Apr 2002 B1
6419695 Gabbay Jul 2002 B1
6458153 Bailey et al. Oct 2002 B1
6468660 Ogle et al. Oct 2002 B2
6488702 Besselink Dec 2002 B1
6517576 Gabbay Feb 2003 B2
6533810 Hankh et al. Mar 2003 B2
6582464 Gabbay Jun 2003 B2
6610088 Gabbay Aug 2003 B1
6623518 Thompson et al. Sep 2003 B2
6685625 Gabbay Feb 2004 B2
6719789 Cox Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6783556 Gabbay Aug 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6814746 Thompson et al. Nov 2004 B2
6830584 Seguin Dec 2004 B1
6869444 Gabbay Mar 2005 B2
6893460 Spenser et al. May 2005 B2
6908481 Cribier Jun 2005 B2
7018406 Seguin et al. Mar 2006 B2
7025780 Gabbay Apr 2006 B2
7137184 Schreck Nov 2006 B2
7160322 Gabbay Jan 2007 B2
7247167 Gabbay Jul 2007 B2
7267686 DiMatteo et al. Sep 2007 B2
7311730 Gabbay Dec 2007 B2
7374573 Gabbay May 2008 B2
7381218 Schreck Jun 2008 B2
7452371 Pavcnik et al. Nov 2008 B2
7510572 Gabbay Mar 2009 B2
7524331 Birdsall Apr 2009 B2
RE40816 Taylor et al. Jun 2009 E
7585321 Cribier Sep 2009 B2
7682390 Seguin Mar 2010 B2
7731742 Schlick et al. Jun 2010 B2
7803185 Gabbay Sep 2010 B2
7846203 Cribier Dec 2010 B2
7846204 Letac et al. Dec 2010 B2
7914569 Nguyen et al. Mar 2011 B2
D648854 Braido Nov 2011 S
D652926 Braido Jan 2012 S
D652927 Braido et al. Jan 2012 S
D653341 Braido et al. Jan 2012 S
D653342 Braido et al. Jan 2012 S
D653343 Ness et al. Jan 2012 S
D654169 Braido Feb 2012 S
D654170 Braido et al. Feb 2012 S
D660432 Braido May 2012 S
D660433 Braido et al. May 2012 S
D660967 Braido et al. May 2012 S
D684692 Braido Jun 2013 S
8840663 Salahieh et al. Sep 2014 B2
9636222 Oslund May 2017 B2
9687342 Figulla Jun 2017 B2
20020036220 Gabbay Mar 2002 A1
20030023303 Palmaz et al. Jan 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030130726 Thorpe et al. Jul 2003 A1
20040049262 Obermiller et al. Mar 2004 A1
20040093075 Kuehne May 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20050096726 Sequin et al. May 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050240200 Bergheim Oct 2005 A1
20050256566 Gabbay Nov 2005 A1
20060008497 Gabbay Jan 2006 A1
20060074484 Huber Apr 2006 A1
20060122692 Gilad et al. Jun 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060173532 Flagle et al. Aug 2006 A1
20060178740 Stacchino et al. Aug 2006 A1
20060195180 Kheradvar et al. Aug 2006 A1
20060206202 Bonhoeffer et al. Sep 2006 A1
20060241744 Beith Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060259120 Vongphakdy et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060265056 Nguyen et al. Nov 2006 A1
20060276813 Greenberg Dec 2006 A1
20070010876 Salahieh et al. Jan 2007 A1
20070027534 Bergheim et al. Feb 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070055358 Krolik et al. Mar 2007 A1
20070067029 Gabbay Mar 2007 A1
20070093890 Eliasen et al. Apr 2007 A1
20070100435 Case et al. May 2007 A1
20070118210 Pinchuk May 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070233228 Eberhardt et al. Oct 2007 A1
20070244545 Birdsall et al. Oct 2007 A1
20070244552 Salahieh et al. Oct 2007 A1
20070288087 Fearnot et al. Dec 2007 A1
20080021552 Gabbay Jan 2008 A1
20080039934 Styrc Feb 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080082164 Friedman Apr 2008 A1
20080097595 Gabbay Apr 2008 A1
20080114452 Gabbay May 2008 A1
20080125853 Bailey et al. May 2008 A1
20080140189 Nguyen et al. Jun 2008 A1
20080147183 Styrc Jun 2008 A1
20080154355 Benichou et al. Jun 2008 A1
20080154356 Obermiller et al. Jun 2008 A1
20080243245 Thambar et al. Oct 2008 A1
20080255662 Stacchino et al. Oct 2008 A1
20080262602 Wilk et al. Oct 2008 A1
20080269879 Sathe et al. Oct 2008 A1
20090112309 Jaramillo et al. Apr 2009 A1
20090138079 Tuval et al. May 2009 A1
20090198315 Boudjemline Aug 2009 A1
20100004740 Seguin et al. Jan 2010 A1
20100036484 Hariton et al. Feb 2010 A1
20100049306 House et al. Feb 2010 A1
20100087907 Lattouf Apr 2010 A1
20100131055 Case et al. May 2010 A1
20100168778 Braido Jul 2010 A1
20100168839 Braido et al. Jul 2010 A1
20100185277 Braido et al. Jul 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100204781 Alkhatib Aug 2010 A1
20100204785 Alkhatib Aug 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100249911 Alkhatib Sep 2010 A1
20100249923 Alkhatib et al. Sep 2010 A1
20100286768 Alkhatib Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20110029072 Gabbay Feb 2011 A1
20120303116 Gorman, III et al. Nov 2012 A1
20150196390 Ma Jul 2015 A1
Foreign Referenced Citations (38)
Number Date Country
19857887 May 2005 DE
10121210 Nov 2005 DE
102005003632 Aug 2006 DE
102005052628 May 2007 DE
202008009610 Dec 2008 DE
0850607 Jul 1998 EP
1000590 May 2000 EP
1584306 Oct 2005 EP
1598031 Nov 2005 EP
1360942 Dec 2005 EP
1849440 Oct 2007 EP
1926455 Jun 2008 EP
2847800 Jun 2004 FR
2850008 Jul 2004 FR
9117720 Nov 1991 WO
9716133 May 1997 WO
9832412 Jul 1998 WO
9913801 Mar 1999 WO
01028459 Apr 2001 WO
0149213 Jul 2001 WO
01054625 Aug 2001 WO
01056500 Aug 2001 WO
01076510 Oct 2001 WO
0236048 May 2002 WO
0247575 Jun 2002 WO
02067782 Sep 2002 WO
03047468 Jun 2003 WO
2005070343 Aug 2005 WO
06073626 Jul 2006 WO
2007053243 May 2007 WO
07071436 Jun 2007 WO
08070797 Jun 2008 WO
10008548 Jan 2010 WO
10008549 Jan 2010 WO
10096176 Aug 2010 WO
10098857 Sep 2010 WO
2012095116 Jul 2012 WO
2013037519 Mar 2013 WO
Non-Patent Literature Citations (16)
Entry
International Search Report for Application No. PCT/US2015/031691 dated Aug. 14, 2015.
Ruiz, Carlos, Overview of PRE-CE Mark Transcatheter Aortic Valve Technologies, Euro PCR, dated May 25, 2010.
Percutaneous aortic valve replacement: resection before implantation, 836-840, Quaden, Rene et al., European J. of Cardio-thoracic Surgery, 27 (2005).
Catheter-implanted prosthetic heart valves, Knudsen, L.L., et al., The International Journal of Artificial Organs, vol. 16, No. 5 1993, pp. 253-262.
Transluminal Aortic Valve Placement, Moazami, Nader, et al., ASAIO Journal, 1996; 42:M381-M385.
Transluminal Catheter Implanted Prosthetic Heart Valves, Andersen, Henning Rud, International Journal of Angiology 7:102-106 (1998).
Transluminal implantation of artificial heart valves, Andersen, H.R., et al., European Heart Journal (1992) 13, 704-708.
Is It Reasonable to Treat All Calcified Stenotic Aortic Valves With a Valved Stent?, 579-584, Zegdi, Rachid, MD, PhD et al., J. of the American College of Cardiology, vol. 51, No. 5, Feb. 5, 2008.
“Direct-Access Valve Replacement”, Christoph H. Huber, et al., Journal of the American College of Cardiology, vol. 46, No. 2, (Jul. 19, 2005).
“Percutaneous Aortic Valve Implantation Retrograde From the Femoral Artery”, John G. Webb et al., Circulation, 2006; 113:842-850 (Feb. 6, 2006).
“Minimally invasive cardiac surgery”, M. J. Mack, Surgical Endoscopy, 2006, 20:S488-S492, DOI: 10.1007/s00464-006-0110-8 (presented Apr. 24, 2006).
“Transapical Transcatheter Aortic Valve Implantation in Humans”, Samuel V. Lichtenstein et al., Circulation. 2006; 114: 591-596 (Jul. 31, 2006).
“Closed heart surgery: Back to the future”, Samuel V. Lichtenstein, The Journal of Thoracic and Cardiovascular Surgery, vol. 131, No. 5, pp. 941-943.
“Transapical approach for sutureless stent-fixed aortic valve implantation: experimental results”; Th. Walther et al., European Journal of Cardio-thoracic Surgery 29 (2006) 703-708 (Jan. 30, 2006).
“Transapical aortic valve implantation: an animal feasibility study”; Todd M. Dewey et al., The annals of thoracic surgery 2006; 82: 110-6 (Feb. 13, 2006).
Textbook “Transcatheter Valve Repair”, 2006, pp. 165-186.
Related Publications (1)
Number Date Country
20170079785 A1 Mar 2017 US
Provisional Applications (1)
Number Date Country
62001793 May 2014 US